Abologix is a biopharmaceutical company focused on developing innovative monoclonal antibodies targeting specific proteins involved in cancer progression. The company is working on two primary targets: Junction Adhesion Molecule C (JAM-C) and Olfactomedin-like protein 3 (Olfml3). JAM-C is known to be expressed in certain lymphocytes and is prominently localized in the tight junctions of endothelial cells, making it a significant target in lymphoma treatment. Abologix aims to leverage its research on JAM-C, which has been extensively studied for over a decade, to create therapies that can inhibit tumor growth and metastasis.

In addition to JAM-C, Abologix is also developing monoclonal antibodies against Olfactomedin-like protein 3 (Olfml3), which is associated with angiogenesis in tumors and is overexpressed in various cancers. By blocking Olfml3, the company seeks to create new generation inhibitors that can effectively disrupt the angiogenic environment that supports tumor growth. This dual-target approach positions Abologix at the forefront of cancer therapeutics, with the potential to address multiple oncological indications through its innovative antibody development strategies.

Switzerland

Abologix is a biopharmaceutical company based in Geneva, Switzerland. The company is a spin out from the laboratories of Prof. Beat Imhof and Thomas Matthes at the University of Geneva and the Geneva University Hospitals.

The company is developing two monoclonal antibodies that selectively block two novel pharmacological targets. Several oncological medical indications are being pursued.

Abologix

Company Details